- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Dyne Therapeutics, Inc. submitted a Biologics License Application (BLA) to the FDA for its product z-rostudirsen.
3 reports, 3 independent
Updated Sep 8
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dyne Therapeutics, Inc. submitted a Biologics License Application (BLA) to the FDA for its product z-rostudirsen.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.